The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2020 ASCO Update on MSI-H mCRC: Is Pembrolizumab More Beneficial Than Chemotherapy in 1L Disease?

0 views
September 9, 2020
Comments 0
Login to view comments. Click here to Login